Search results
Will GSK Stock Rebound To Its 2022 Highs Of $47?
Forbes· 1 day agoGSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022.
Should We Be Delighted With GSK plc's (LON:GSK) ROE Of 36%?
Simply Wall St. via Yahoo Finance UK· 2 days agoWhile some investors are already well versed in financial metrics (hat tip), this article is for...
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
Zacks via Yahoo Finance UK· 2 days agoGSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration...
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Zacks via Yahoo Finance UK· 2 days agoIt was a regular week for the biotech sector with quite a few important pipeline and regulatory...
GSK takes full control of flu vaccine programme in €1.45bn deal
Proactive Financial News· 3 days agoGSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new...
GSK to Pay CureVac Up to €1.4 Billion for Flu, Covid Shots
Bloomberg· 3 days agoHave a confidential tip for our reporters? GSK Plc agreed to pay as much as €1.4 billion ($1.5...
GSK and CureVac to Restructure Collaboration into New Licensing Agreement (1)
PharmiWeb· 3 days agoLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today ...
GSK buys full rights to make COVID, influenza vaccines from CureVac
Reuters· 3 days agoGSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine...
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
Zacks via Yahoo Finance UK· 5 days agoModerna’s stock also took a hit last week after it presented new data on mResvia to the CDC, which...
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge
Reuters· 5 days ago, opens new tab and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming...